ProCE Banner Activity

Phase II Trial of CPX-351 as First-line Treatment in Patients With Higher-Risk MDS

Slideset Download
Conference Coverage
Results from a phase II trial indicate that CPX-351 is as effective as first-line therapy in patients with higher-risk MDS, particularly to achieve blast clearance and as a bridge to allogeneic SCT.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation